CIK 0001438533 · Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 262383102
- Phone
- 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $79,812,468
- in 11 filings, $79.8M under 10b5-1 plans
Net −$79,812,468. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-06 | Baynes Roy D. Director | Option exercise 10b5-1 | +10,000 | $26.52 | $265K | 47,500 |
| 2026-04-06 | Baynes Roy D. Director | Sale 10b5-1 | −10,000 | $33.00 | $330K | 37,500 |
| 2026-04-06 | Baynes Roy D. Director | Option exercise · Stock option (right to buy) 10b5-1 | −10,000 | 0 | ||
| 2026-04-01 | Dube Eric M CHIEF EXECUTIVE OFFICER | Option exercise 10b5-1 | +60,000 | $15.46 | $928K | 492,886 |
| 2026-04-01 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −34,902 | $30.55 | $1.1M | 457,984 |
| 2026-04-01 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −25,098 | $31.46 | $790K | 432,886 |
| 2026-04-01 | Dube Eric M CHIEF EXECUTIVE OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −60,000 | 0 | ||
| 2026-04-01 | REED ELIZABETH E Chief Legal Officer and GC | Option exercise 10b5-1 | +10,000 | $15.46 | $155K | 115,211 |
| 2026-04-01 | REED ELIZABETH E Chief Legal Officer and GC | Sale 10b5-1 | −10,000 | $30.00 | $300K | 105,211 |
| 2026-04-01 | REED ELIZABETH E Chief Legal Officer and GC | Option exercise · Employee stock option (right to buy) 10b5-1 | −10,000 | 45,000 | ||
| 2026-03-16 | REED ELIZABETH E Chief Legal Officer and GC | Option exercise 10b5-1 | +10,000 | $19.08 | $191K | 115,211 |
| 2026-03-16 | REED ELIZABETH E Chief Legal Officer and GC | Sale 10b5-1 | −10,000 | $28.09 | $281K | 105,211 |
| 2026-03-16 | REED ELIZABETH E Chief Legal Officer and GC | Option exercise · Employee stock option (right to buy) 10b5-1 | −10,000 | 10,000 | ||
| 2026-02-20 | Dube Eric M CHIEF EXECUTIVE OFFICER | Option exercise 10b5-1 | +60,000 | $15.46 | $928K | 492,886 |
| 2026-02-20 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −60,000 | $30.10 | $1.8M | 432,886 |
| 2026-02-20 | Dube Eric M CHIEF EXECUTIVE OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −60,000 | 60,000 | ||
| 2026-02-17 | REED ELIZABETH E Chief Legal Officer and GC | Option exercise 10b5-1 | +10,000 | $19.08 | $191K | 115,211 |
| 2026-02-17 | REED ELIZABETH E Chief Legal Officer and GC | Sale 10b5-1 | −5,679 | $27.50 | $156K | 109,532 |
| 2026-02-17 | REED ELIZABETH E Chief Legal Officer and GC | Sale 10b5-1 | −4,321 | $28.26 | $122K | 105,211 |
| 2026-02-17 | REED ELIZABETH E Chief Legal Officer and GC | Option exercise · Employee stock option (right to buy) 10b5-1 | −10,000 | 20,000 |
Page 12 of 51 · 1,020 trades